Study of Intratumoral Selicrelumab With Atezolizumab in Patients With Refractory or Relapsed B Cell Lymphoma
Status:
Terminated
Trial end date:
2021-04-07
Target enrollment:
Participant gender:
Summary
This is a multicenter, open, dose escalation phase Ib trial of intratumoral agonistic
anti-CD40 Ab (Selicrelumab intratumoral every 3 weeks for 3 cycles) in combination with
anti-PDL1 Ab (Atezolizumab 1200mg intravenous every 3 weeks) in patients with refractory or
relapsed B cell lymphoma